세계 윌름스 종양 치료 시장 – 2023-2030

Market Overview
Global Wilms Tumor Treatment Market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.2 billion by 2030 growing with a CAGR of 4.7% during the forecast period 2023-2030. The trend such as the shift towards personalized medicine by better understanding of specific gene mutations associated with this tumor is expected to dominate the global wilms tumor treatment market.
The global wilms tumor treatment market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such as the usage of targeted therapies, precision medicine, genetic profiling, and emerging immunotherapy options.
Furthermore, the rising prevalence of wilms tumor treatment, advancements in diagnostic technologies, increasing awareness and screening programs, and also the increasing susceptibility of other syndromes such as WAGR syndrome and Denys-Drash syndrome that results in wilms tumor are driving up the wilms tumor treatment market size. The rising number of clinical trials has resulted in the development of novel treatments is seeing an increase in demand from North American regions. With significant competitors like Cepham Life Sciences , Pfizer Inc., Fresenius Kabi AG, and others actively operating in the market.
Market Dynamics
The Increasing Prevalence of Wilms Tumor to Drive the Growth of the Wilms Tumor Treatment Market
The global wilms tumor treatment market is growing rapidly, owing mainly due an increase in wilms tumor treatment diagnoses worldwide. This tumor develops in children and is a form of kidney cancer. For instance, according to the American Society of Clinical Oncology (ASCO) 2023 report, approximately 500-600 children in U.S. every year are diagnosed with this tumor. This tumor accounts 4% of all types of cancer found in children.
Furthermore, the prevalence of wilm tumor is common in girls in compare to boys and black children are more susceptible to these tumor rather than white. Wilms tumor can develop in one or both kidneys. Moreover, 5 to 10 percent of affected individuals develop multiple tumors in one or both kidneys. Thus, owing to the increase in prevalence of the wilms tumor market is expected to drive over the forecast period.
The Advancements in Identification of the Tumor will Drive the Market Growth
The advances in identification of the tumor using biomarker is expected to dominate the market. Due to the factors such as the biomarkers play a pivotal role by enabling early detection and diagnosis, providing personalized treatment framework through molecular profiling, monitoring the treatment response, and reducing invasive procedures.
For instance, according to the researcher, wilms tumors with favorable histology and modifications in chromosome 1q are more likely to recur following treatment. Biomarkers may be utilized in the future to identify patients who are at high risk of recurrence. Moreover, as the blood and urine samples are readily available, all biomarkers can be managed and monitored efficiently.
The Emergence of Other Types of Syndrome will Drive the Market Growth
The emergence of syndromes such as Beckwith-Wiedemann syndrome, WAGR syndrome, and Denys-Drash syndrome (also known as Drash syndrome) could possibly be associated with Wilms tumor. The Denys-Drash syndrome lead to abnormal kidney function, it is also related disorder of sexual development in affected males.
For instance, according to Cleveland Clinic report, the children suffering with Denys-Drash conditions are on verge of developing with wilms syndrome of approximate 90% probability. Moreover, the children suffering with WAGR syndrome have 50% chances of developing wilms tumor. Thus, owing to the increased prevalence of these syndromes the chances of developing the wilms tumor is significant and is therefore anticipated that the market is expected to grow over the forecast period.
The Side Effects Associated For Wilms Tumor Treatment Will Hamper the Growth of the Market
The wilms tumor treatment market is expected to be hamper owing to the factors such as side effects from cancer drugs. The chemotherapy is expected to result in various side effects such as hair loss, loss of appetite, and low white blood cells count. Furthermore, in radiation therapy, the high X-ray energy may lead to several side effects too.
Moreover, the cost associated with this treatment is quite expensive. For instance, in India the average cost including treatment, surgery, and radiation therapy ranges from 534 USD to 1335 USD. Thus, owing to the above factors the market is expected to face a major restraint over the forecast period.
Segment Analysis
The global wilms tumor treatment market is segmented based on types, treatment, end user, and region.
Owing to its Better Effectiveness, the Surgery Segment Accounted for Approximately 43.2% of the Wilms Tumor Treatment Market Share
The surgery segment is poised to dominate the wilms tumor treatment market as it remains a first-line and preferred medical treatment for wilms tumor treatment owing to its effectiveness, advancements in technologies, and increasing clinical trials for wilms tumor treatment. The main goal of surgery is to remove the entire Wilms tumor in one piece, if possible. Different types of surgeries are performed such as radical nephrectomy and partial nephrectomy.
For instance, St. Jude Children's Research Hospital is conducting a clinical trial to evaluate the treatment of newly diagnosed wilm's tumour patients requiring abdominal radiation delivered with proton beam irradiation. Participants in the trial must have been diagnosed with wilms tumour cancer and require abdominal radiotherapy. The trial's primary goal is to assess the safety and efficacy of proton beam irradiation in the treatment of Wilms tumour. Currently the trial is in phase 2 and estimated completion period of trial is December 2026. Thus, owing to the above factors the segment is expected to dominate over the forecast period.
Geographical Penetration
North America Accounted for Approximately 41.9% of the Market Share in 2022, Owing to the Presence of Hospitals and Research Associations
North America, particularly the U.S., dominates the global wilms tumor treatment market due to its presence of established market players, along with presence of renowned research hospitals. Furthermore, the increasing number of clinical trials led to novel treatments for better patient outcomes.
For instance, most of the wilms tumor research in the United States is coordinated by the Children's Oncology Group (COG), whose primary mission is to enhance the treatment and quality of life of children with wilms tumor and other types of cancer. COG is a vast network of doctors, nurses, scientists, and other health professionals whose efforts have already saved the lives of numerous children with Wilms tumors. Wilms tumor genetics is still being studied to learn how variations in certain genes generate wilms tumors and influence how aggressive these tumors are likely to be.
Morover, most children in Canada are treated using the National Wilms Tumour Study (NWTS) and Children's Oncology Group (COG) protocols. Over the last 20 years, there has been significant progress in treating Wilms tumor, with overall survival rates above 90%. Thus, owing to the factor stated above, the market in this region is expected to grow over the forecast period.
Competitive Landscape
The major global players in the wilms tumor treatment market include Cepham Life Sciences, Pfizer Inc., Getwell Pharmaceuticals, Amneal Pharmaceuticals LLC, Medline Industries, LP., Sandoz International GmbH, Teva Canada Limited, Accord Healthcare Ireland Ltd., Eugia US LLC, Fresenius Kabi AG, and among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a mild influence on global wilms tumor market growth. The Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, as well as elective surgeries, be postponed unless the risks outweighed the benefits and the hospital infrastructure was secure for the treatment of COVID-19 patients. As a result, the COVID-19 pandemic has also hampered ongoing clinical trials.
However, the situation is likely to improve gradually. COVID-19 may have no effect on renal function in patients with WAGR syndrome, which includes Wilms tumour. Another study discovered that COVID-19 had little effect on pediatric cancer patients, and those who are affected are typically asymptomatic or have minimal disease.
The COVID-19 pandemic, on the other hand, has had a severe influence on paediatric cancer care, including delays in diagnosis and treatment. According to one study, the COVID-19 pandemic temporarily altered the tumour features of children with kidney tumours, including Wilms Tumour. The long-term impact on clinical outcomes will be monitored. To maintain the safety and well-being of paediatric cancer patients throughout the pandemic, it is critical to constantly monitoring the situation and taking required precautions.
Russia Ukraine Conflict Analysis
The Russia-Ukraine conflict is having a impact on the global wilms tumor treatment market. The conflict has decreased access to healthcare services in Ukraine, making it harder for wilms tumor treatment patients to receive critical treatment. The increased financial load on patients as a result of treatment costs and economic instability has further hampered access to care. Delayed diagnosis and treatment have also been noted as people are unwilling to seek medical help during the conflict.
These obstacles have had a detrimental impact on the global wilms tumor treatment market, producing slower growth than expected. However, there is potential for development, such as a greater emphasis on creating more effective treatment options and improving wilms tumor treatment awareness in Ukraine. As the war ends and healthcare access improves, the market is projected to rebound. Nonetheless, the conflict's impact on the market is still enormous, necessitating continual efforts to handle the problems and opportunities it brings.
By Type
• Favorable Histology
• Anaplastic Histology
By Treatment
• Surgery
o Radical Nephrectomy
o Partial Nephrectomy
o Others
• Chemotherapy
• Radiation Therapy
• Others
By End Users
• Hospitals
• Cancer Research Center
• Academic and Research Institutes
• Others
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On May 11, 2022, Cue Biopharma, Inc., a clinical-stage biopharmaceutical company developing a novel class of injectable biologics, announced that the FDA has approved the Company's Investigational New Drug (IND) application for the evaluation of CUE-102, its second interleukin 2 (IL-2)-based CUE-100 series biologic, in a dose escalation and expansion monotherapy Phase 1 trial with a starting dose of 1 mg/kg for the treatment of Wilms' tumour.
Why Purchase the Report?
• To visualize the global wilms tumor treatment market segmentation based on type, treatment, end user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of wilms tumor treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in Excel consisting of key products of all the major players.
The global wilms tumor treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies